2023 World Conference on Lung Cancer (Posters)-EP08.02. Management of Inoperable Locally Advanced Stage III ALK fusion Positive NSCLC: A Retrospective Multi-institutional Analysis

EP08.02. Management of Inoperable Locally Advanced Stage III ALK fusion Positive NSCLC: A Retrospective Multi-institutional Analysis - PDF(Abstract)

Back to course

Pdf Summary

The study presented in this abstract aimed to analyze the management of inoperable locally advanced stage III ALK fusion positive non-small cell lung cancer (NSCLC). The researchers utilized a prospectively maintained database at the Shanghai Chest Hospital to identify patients treated for inoperable stage III ALK NSCLC between 2017 and 2022. The patients were divided into three groups based on the therapy they received: chemotherapy alone, chemoradiation (CRT) without ALK-TKI (tyrosine kinase inhibitor), and ALK-TKI with or without chemotherapy. The time to progression (TTP) was compared between the three treatment groups using the log-rank test and Kaplan-Meier method.<br /><br />Out of 58,202 patients treated during the study period, 169 were included in the analysis. The median TTP was found to be shorter in patients treated with chemotherapy alone (8.6 months) compared to those managed with chemoradiation (14.6 months) or ALK-TKI (17.8 months). There was a statistically significant difference in TTP between patients treated with ALK-TKI and chemoradiation, as well as between ALK-TKI and chemotherapy as first-line treatment.<br /><br />The findings suggest that when used as a first-line therapy, chemoradiation, ALK-TKI with or without chemotherapy, and chemotherapy alone can achieve different TTP in patients with inoperable stage III ALK fusion positive NSCLC. The prognosis for patients treated with ALK-TKI was found to be superior to that of patients receiving chemotherapy or chemoradiation. However, further studies are needed to determine the efficacy of ALK-TKI as first-line or maintenance therapy for these patients.<br /><br />The baseline characteristics of the patients, such as age, sex, stage at diagnosis, performance status score, smoking status, pathology type, and ALK test method, were also reported.<br /><br />In summary, this retrospective multi-institutional analysis highlights the different TTP achieved with different treatment modalities for inoperable stage III ALK fusion positive NSCLC. The results suggest that ALK-TKI may be a more favorable option as a first-line therapy in these patients, but further investigation is needed.

Asset Subtitle

Shun Lu

Meta Tag

Speaker Shun Lu

Topic Local-Regional NSCLC: Multimodality Therapy

Keywords

inoperable

stage III

ALK fusion positive

NSCLC

chemotherapy

chemoradiation

ALK-TKI

time to progression

prognosis

first-line treatment